Comparison · NCT02684006-aa187230
Avelumab + Axitinib vs Sunitinib: Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Avelumab + Axitinib vs Sunitinib: Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue. Trial comparisons, record NCT02684006-aa187230. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02684006-aa187230
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.67 | 0.622 | 0.714 | wilson | |
| Risk in group 2 | 0.708 | 0.662 | 0.75 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0376 | -0.101 | 0.0263 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.947 | 0.863 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.839 | 0.622 | 1.13 | log | |
| Number needed to treat, for one fewer participant with the outcome on Avelumab + Axitinib than on Sunitinib | 26.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Avelumab + Axitinib | Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days. | 266 | 397 | OG000 |
| Group 2 | Sunitinib | Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days. | 288 | 407 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue
- Description
Tumor biospecimens from pre-treatment tissue samples were analyzed by immunohistochemistry for PD-L1 biomarker expression. Number of participants with positive PD-L1 biomarker expression are reported in this outcome measure.
- Time frame
- At screening
- Population
Biomarker analysis set for biomarkers that are measured only at screening, included all participants who received at least one dose of study drug and who had at least one screening biomarker assessment. Here Number of Participants Analyzed signifies participants evaluable for this outcome measure.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
- NCT number
- NCT02684006
- Phases
- PHASE3
- Conditions
- Renal Cell Cancer
- Interventions
- Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
- Lead sponsor
- Pfizer
- Results first posted
- 2024-10-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02684006?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02684006-aa187230